FDA Advisers Urge Approval of Cangene’s Botulism-Fighting Biologic

Drug Industry Daily
A A
Citing scarce treatment options for botulism, the FDA’s Blood Products Advisory Committee has recommended approval of Cangene’s botulinum antitoxin derived from equine sources.

To View This Article:

Login

Subscribe To Drug Industry Daily